Financial Proceeds Utilization - The net proceeds from the rights issue amount to approximately HKD 330.0 million, with about HKD 39.6 million remaining unutilized as of December 31, 2023[1]. - The company plans to utilize approximately HKD 39.6 million of the unutilized proceeds for acquiring equity in pharmaceutical companies engaged in the pharmaceutical business overseas and/or domestically in China, as well as for general working capital[2]. - The company has allocated approximately HKD 17.3 million of the unutilized proceeds for the acquisition of 16% of the issued share capital of China Nüwa Pharmaceutical Group Co., Ltd., which primarily operates in the domestic pharmaceutical business in China[10]. - The remaining unutilized proceeds of approximately HKD 22.3 million are planned to be used as general working capital for the group[10]. - The company intends to expand the proposed use of unutilized proceeds to cover general operations and domestic pharmaceutical business in China, excluding overseas pharmaceutical operations[9]. Business Strategy and Market Focus - The company aims to enhance its product portfolio and distribution channels to better capture opportunities in the domestic Chinese market[9]. - The company has adopted a cautious approach in seeking suitable business or investment opportunities due to economic instability and the impact of the COVID-19 pandemic[9]. Corporate Governance - The board of directors includes key members such as Chairwoman Wang Qiuxin and other executive directors[7]. - The company emphasizes that the supplementary information provided does not affect the contents of the annual report, which remains unchanged[6]. - The announcement clarifies that the Hong Kong Stock Exchange and the Hong Kong Exchanges and Clearing Limited bear no responsibility for the accuracy or completeness of the announcement[8].
新锐医药(06108) - 2024 - 年度业绩